The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Sep. 27, 2:56 AM

Slide #12. CareDx, Inc. Secondary Offering

Company: CareDx, Inc. (NASDAQ:CDNA)
Date announced: 9/20/2016
Shares Offered: 2,250,000
Date of Pricing: 9/21/2016
Price Per Share: $4.00
Secondary Offering Details: CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. CareDx also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx. -updated 9/21- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of its public offering of 2.25 million shares of its common stock at a price to the public of $4.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 337,500 additional shares of its common stock. All of the shares will be offered and sold by CareDx.

CareDx is a molecular diagnostics company focused on the discovery, development and commercialization of diagnostic surveillance solutions for transplant patients. Co.'s commercialized testing solution, the AlloMap heart transplant molecular test, is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. Co. is also engaged in the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its proprietary sequencing test to detect donor-derived cell-free DNA after transplantation.
Open the CDNA Page at The Online Investor »

Company Name:  CareDx Inc
Website:  www.caredxinc.com
Sector:  Diagnostics
Number of ETFs Holding CDNA:  2
Total Market Value Held by ETFs:  $78975
Total Market Capitalization:  $40.00M
% of Market Cap. Held by ETFs:  0.20%
 

Open the CDNA Page at The Online Investor (in a new window) »

September 27, 2016    2:56 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.60 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.